Equities

Glycorex Transplantation AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Glycorex Transplantation AB (publ)

Actions
  • Price (SEK)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.9556
Data delayed at least 20 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Glycorex Transplantation AB (publ) is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. The Company’s medical devices enable transplants across the blood groups saving lives and providing health economic benefits by increasing the number of transplants.

  • Revenue in SEK (TTM)39.94m
  • Net income in SEK-7.06m
  • Incorporated1995
  • Employees20.00
  • Location
    Glycorex Transplantation AB (publ)Scheelevagen 27LUND 223 63SwedenSWE
  • Phone+46 462865230
  • Fax+46 462865239
  • Websitehttps://glycorex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.